Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Neoplasms 5Neoplasm Metastasis 2Vomiting 1Urinary Bladder Neoplasms 1TP53 Y220C Mutation 1Solid Tumors 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Nausea 1Myofibroma 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Carcinoma 1Breast Neoplasms 1Advanced Solid Tumors 1Advanced Cancer 1Adenocarcinoma of Lung 1

Interventions

Cytarabine 146Azacitidine 99venetoclax 95Cyclophosphamide 70fludarabine 69Decitabine 63fludarabine phosphate 55Specimen Handling 35Filgrastim 35Daunorubicin 34Mitoxantrone 30Idarubicin 29Etoposide 27Injections 25Granulocyte Colony-Stimulating Factor 25Biopsy 24Busulfan 22Tacrolimus 21Clofarabine 21Mycophenolic Acid 18Melphalan 18Methotrexate 17Bortezomib 17Whole-Body Irradiation 16Stem Cell Transplantation 16Peripheral Blood Stem Cell Transplantation 16Vorinostat 15Gemtuzumab 15Lenalidomide 14decitabine and cedazuridine drug combination 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Myeloid, Acute × Tablets × Clear all
NCT05330377 2023-04-25

GM-CLAG in Relapsed/Refractory FLT3-mutated AML

University of Kentucky

Phase 1 Withdrawn
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡